Find new angles and add context for your readers, with the same knowledge base and analysts top pharma and biotech companies use for their biggest decisions.
Trace deal activity, map a competitive landscape, or check a number before you print it. Sleuth’s analysts turn your question into sourced data you can use, on your deadline.
Send the question in the morning and get a sourced count, list, or chart back the same day.
For a bigger story, the analysts work the question with you until the data shows what’s happening, with a source for every row.
Read select Sleuth Intelligence reports before they go public, with time to ask questions and find your own angle.
Talk to Sleuth’s cofounder and analysts about what the data shows, and what it doesn’t.
A question can lead to a sourced dataset, a chart, a competitive landscape, or an on-the-record interview with a Sleuth analyst, depending on the story and your deadline.
Tell Sleuth what you cover and what you want to watch, and Sleuth builds a tracker around it, with every row linked to its source. It’s updated after each company reports earnings, or whenever you ask.
You choose what it follows
A set of companies, a target, a modality, or an indication.
You choose what it tracks
Pipeline changes, approvals and filings, readouts, new trials, deals, or the catalysts companies guide to.
The programs behind every count
Click a count to see the programs behind it and where each one came from.
Reporters at the Wall Street Journal, the Financial Times, Fierce Biotech, STAT, and BioSpace have built stories on Sleuth’s data.
Sleuth mapped all 276 HER2-targeted ADCs in development for Fierce, from their payloads to where they come from, and found only 20 trials enrolling HER2-positive breast cancer patients after a HER2 ADC. One is a Phase 3 after Enhertu.
“There should be earlier recognition in the industry about this type of commercial dynamic.”
Andrew Pannu
Sleuth’s analysts publish deep dives on the fields everyone is watching. Cite them, or ask for the data behind a chart.
The report behind the Wall Street Journal’s October 15 story on protein degraders.
The report behind BioSpace’s forecast of more Western deals for Chinese radioligand therapies in 2027.
China-originated ADCs supply 12 of the 14 Phase 3 ADC readouts at ESMO 2026.
Tell us about your beat and publication. We’ll follow up to work out your first question.
What happens next
1
Tell us your beat and what you’re working on.
2
Sleuth follows up to work out your first question.
3
The analysts build the data, chart, or tracker for your story, on your deadline.